Humana (HUM) EBITDA (2009 - 2026)

Humana has reported EBITDA for 18 years, with the latest figure at $1.9 billion in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 12.51% year-over-year to $1.9 billion; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (down 24.21% YoY), and the FY2025 full-year result was $3.5 billion, changed 0.2% from the prior year.
• EBITDA for Q1 2026 stood at $1.9 billion, up from -$622.0 million in the prior quarter.
• The five-year high for EBITDA was $2.2 billion in Q1 2025, with the low at -$622.0 million in Q4 2025.
• Average EBITDA over 5 years is $1.1 billion, with a median of $1.4 billion recorded in 2024.
• Year-over-year, EBITDA surged 969.29% in 2022 and plunged 151.59% in 2024.
• Tracing HUM's EBITDA over 5 years: stood at $318.0 million in 2022, then tumbled by 139.62% to -$126.0 million in 2023, then sank by 151.59% to -$317.0 million in 2024, then tumbled by 96.21% to -$622.0 million in 2025, then jumped by 411.41% to $1.9 billion in 2026.
• The last three EBITDA figures came in at $1.9 billion (Q1 2026), -$622.0 million (Q4 2025), and $591.0 million (Q3 2025), per Business Quant data.

Peer Comparison